摘要
背景:光动力治疗(PDT)在抗癌研究中是一个日益突出的领域。 PDT试剂通常在没有光的情况下是无毒的,并且可以用非电离辐射刺激以“激活”它们的细胞毒性作用。虽然通过允许选择性治疗的局部照射来控制药物的毒性是有利的,但是光敏染料不被分类为化疗药物。过渡金属是具有各种独特性能的极其多用途的化合物,如氧化态,配位数,氧化还原电位和可根据具体用途量身定制的分子几何结构。这使得它们成为优秀的PDT候选物,因为它们的性质可以被操纵以吸收特定范围的光波长,穿过细胞膜或体外靶向特定位点。本文综述了过渡金属PDT试剂的最新进展,重点介绍了一系列金属配合物合成的结构支架,以及它们在存在或不存在照射时的体外细胞毒性。 结论:临床光敏剂如PhotofrinR的成功激发了数千种潜在PDT药物的开发。特别是过渡金属配合物在涉及PDT治疗浸润性癌症时表现出优异的多功能性和多样性。该综述强调了过渡金属PDT试剂在体外和体内高光毒活性方面的许多最新进展。光敏过渡金属配合物由于其固有的物理化学变化已经证明了它们的潜力,使它们能够填补PDT世界的空白
关键词: 光动力疗法,过渡金属,癌症,辐照,光照,活性氧物种。
Current Medicinal Chemistry
Title:Exposing “Bright” Metals: Promising Advances in Photoactivated Anticancer Transition Metal Complexes
Volume: 25 Issue: 4
关键词: 光动力疗法,过渡金属,癌症,辐照,光照,活性氧物种。
摘要: Background: Photodynamic therapy (PDT) is an increasingly prominent field in anticancer research. PDT agents are typically nontoxic in the absence of light and can be stimulated with nonionising irradiation to “activate” their cytotoxic effect. Photosensitzers are not classified as chemotherapy drugs although it is advantageous to control the toxicity of a drug through localised irradiation allowing for selective treatment. Transition metals are an extremely versatile class of compounds with various unique properties such as oxidation state, coordination number, redox potential and molecular geometry that can be tailored for specific uses. This makes them excellent PDT candidates as their properties can be manipulated to absorb a specific range of light wavelengths, cross cellular membranes or target specific sites in vitro. This article reviews recent advances in transition metal PDT agents, with a focus on structural scaffolds from which several metal complexes in a series are synthesised, as well as their in vitro cytotoxicity in the presence or absence of irradiation.
Conclusion: The success of clinical photoactive agents such as Photofrin® has inspired the development of thousands of potential PDT agents. Transition metal complexes in particular have demonstrated excellent versatility and diversity when it comes to PDT for treatment of invasive cancers. This review has highlighted some of the many recent advances of transition metal PDT agents with high in vitro and in vivo phototoxic activity. Photoactive transition metal complexes have proven their potential due to their inherent physicochemical variety, allowing them to fill a niche in the PDT world.
Export Options
About this article
Cite this article as:
Exposing “Bright” Metals: Promising Advances in Photoactivated Anticancer Transition Metal Complexes, Current Medicinal Chemistry 2018; 25 (4) . https://dx.doi.org/10.2174/0929867324666170530085123
DOI https://dx.doi.org/10.2174/0929867324666170530085123 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Photopolymerizable Resins for 3D-Printing Solid-Cured Tissue Engineered Implants
Current Drug Targets Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets The Association of Very High Hair Manganese Accumulation and High Oxidative Stress in Mongolian People
Current Aging Science Anti-Cancerous Effect of Rutin Against HPV-C33A Cervical Cancer Cells via G0/G1 Cell Cycle Arrest and Apoptotic Induction
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration through the Transcription Factor E2F1 in Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy The Role of ABCG2 and ABCB6 in Porphyrin Metabolism and Cell Survival
Current Pharmaceutical Biotechnology Is Senescence Reversible?
Current Drug Targets Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry A Comprehensive Review on Cross-talk of Human Papilloma Virus Oncoproteins and Developmental/Self-Renewal Pathways During the Pathogenesis of Uterine Cervical Cancer
Current Molecular Medicine Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry